Enzalutamide plus Radium223 Treatment as First-Line for mCRPC in a Nordic Perspective

During ESMO 2024, Silke Gillesen presented the PEACE-3 study that shows that a combination of enzalutamide plus radium223 can be a potential new first-line treatment for patients with castration-resistant prostate cancer with bone metastases who have not received an androgen receptor pathway inhibitor. In this MEDtalk, Gedske Daugaard, Oncology Clinic, Rigshospitalet, Denmark, who has been part of the PEACE-3 study, gives her perspective on the study. She mentions that one of the problems with the results is that this study has been running for eight years. According to that, the standard treatment of prostate cancer has changed along the way.